Find Your Funding Opportunity
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Service
|
Source |
Final Application Due Date |
Funding Available
|
Match Required
|
|---|---|---|---|---|
| Health Care |
Federal
HHS |
01-07-2027 | N/A | No Match Required |
-
Service
-
Source
-
Final Application Due Date
-
Funding Available
-
Match Required
Status
- Opportunity Type Discretionary
-
CFDA
93.121 -- Oral Diseases and Disorders Research
93.213 -- Research and Training in Complementary and Integrative Health
93.233 -- National Center on Sleep Disorders Research
93.273 -- Alcohol Research Programs
93.279 -- Drug Abuse and Addiction Research Programs
93.313 -- NIH Office of Research on Women's Health
93.395 -- Cancer Treatment Research
93.837 -- Cardiovascular Diseases Research
93.838 -- Lung Diseases Research
93.839 -- Blood Diseases and Resources Research
93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research
93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
93.865 -- Child Health and Human Development Extramural Research
93.866 -- Aging Research
93.867 -- Vision Research
Description
Reissue of RFA-NS-20-010: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.
Eligibility
- IHE
- Local Government
- Non-Profit
- Other
- State Government
- Tribal Government
Additional Eligibility Information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Key Date(s)
- October 31, 2023: Posted Date
- November 02, 2023: Last Updated Date
- January 07, 2027: Current Closing Date for Applications
- January 07, 2027: Application Due Date
- February 12, 2027: Application Archive Date
Contact Information
NIH Grants Information
grantsinfo@nih.gov